RENXFOQBHealthcare

RENXF

-70.1% · 90d

$0.02

+0.00 (+0.00%)

News

No News Yet

Press releases and SEC filings for RENXF will appear here as they are published.

Check back later for updates

Key Data

Market Cap$10.3M

Open$0.02

Prev Close$0.02

Day Range$0.02 – $0.02

52W Range$0.02 – $0.18

Volume20,000

P/E (TTM)—

EPS$-0.04

Dividend Yield—

Beta1.97

Revenue Growth2.80%

About

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company's products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. It has a license agreement with Mount Sinai Health System to develop and commercialize its products in connection with the application of artificial intelligence for the diagnosis of kidney disease. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. The company was incorporated in 2018 and is based in London, the United Kingdom.

Healthcare · Health Information Services

46 employees

renalytix.com

Top Institutional Holders

As of 2025-09-30 · prior 2025-06-30

Ironwood Investment Counsel, LLC$2,630

10,000 sh0.0%

See all holders →